Key clinical point: A new beverage containing a palatable blend of specific medium-chain triglycerides may improve compliance among patients on ketogenic diets.
Major finding: Two-thirds of the children and 69% of adults who started the study were still using the study beverage at the 12-week mark.
Study details: A 12-week safety and tolerability study including 35 children with genetically caused forms of epilepsy and 26 adults with drug-resistant epilepsy.
Disclosures: The Betashot study was funded by Vitaflo International.
REPORTING FROM IEC 2019